Asian Firms Tweak Strategy Amid Biosimilars 'Stampede'
This article was originally published in Scrip
Executive Summary
More biosimilar approvals for Asian firms in Western markets building on the success of players like Celltrion and Samsung and a shift away from local/regional development strategies were some of the key trends highlighted at a recent roundtable by Quintiles.